In AML, miR‐126, aberrantly upregulated due to the CBFB–MYH11 fusion gene, directly targets and regulates the SPRED1/PLK2–ERK–MYC axis, enhancing MYC activity and improving antileukemia and anti‐LSC effects.219. Here, MYC is linked to acute myeloid leukemia.